INVOKANA is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Cardinal Health. The primary component is Canagliflozin.
| Product ID | 55154-1426_35f11a41-5a34-41fa-a3cb-a35901229e08 |
| NDC | 55154-1426 |
| Product Type | Human Prescription Drug |
| Proprietary Name | INVOKANA |
| Generic Name | Canagliflozin |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2013-03-29 |
| Marketing Category | NDA / NDA |
| Application Number | NDA204042 |
| Labeler Name | Cardinal Health |
| Substance Name | CANAGLIFLOZIN |
| Active Ingredient Strength | 300 mg/1 |
| Pharm Classes | Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2013-03-29 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA204042 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2013-03-29 |
| Ingredient | Strength |
|---|---|
| CANAGLIFLOZIN | 300 mg/1 |
| SPL SET ID: | 5f76e16f-0c24-454a-81af-4080b312c940 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 50090-4364 | INVOKANA | canagliflozin |
| 50090-5029 | INVOKANA | canagliflozin |
| 50090-5033 | INVOKANA | canagliflozin |
| 50090-5034 | INVOKANA | canagliflozin |
| 50458-140 | INVOKANA | canagliflozin |
| 50458-141 | INVOKANA | canagliflozin |
| 55154-1425 | INVOKANA | canagliflozin |
| 55154-1426 | INVOKANA | canagliflozin |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() INVOKANA 85592280 4369669 Live/Registered |
JOHNSON & JOHNSON 2012-04-09 |